ICER Plans Review of Bladder Cancer Treatment

February 21, 2020

The Institute for Clinical and Economic Review (ICER) announced plans to review FKD Therapies Oy and Ferring Pharmaceuticals’ Instiladrin for the treatment of bladder cancer.

According to a press release, the Food and Drug Administration (FDA) is expected to make a decision on the drug later this year.

ICER is accepting input for the development of an evidence report until 5 p.m. EST March 10.

To see the timeline of this review, click here.

Click here to read the full press release.

Share This Story!